Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has earned an average broker rating score of 1.33 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. Aeglea Bio Therapeutics’ rating score has declined by 33% from 90 days ago as a result of various analysts’ upgrades and downgrades.
Brokerages have set a twelve-month consensus price target of $18.00 for the company and are expecting that the company will post ($0.54) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aeglea Bio Therapeutics an industry rank of 192 out of 265 based on the ratings given to its competitors.
A number of brokerages have issued reports on AGLE. BMO Capital Markets reissued an “outperform” rating and set a $18.00 price objective on shares of Aeglea Bio Therapeutics in a research report on Wednesday, March 14th. Needham & Company LLC boosted their price objective on shares of Aeglea Bio Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, March 14th. Finally, Zacks Investment Research downgraded shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th.
A number of institutional investors have recently modified their holdings of the business. Jennison Associates LLC grew its position in shares of Aeglea Bio Therapeutics by 0.6% in the 4th quarter. Jennison Associates LLC now owns 1,393,439 shares of the biotechnology company’s stock worth $7,539,000 after buying an additional 8,372 shares during the period. Vanguard Group Inc. grew its position in shares of Aeglea Bio Therapeutics by 9.4% in the 2nd quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after buying an additional 12,966 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Aeglea Bio Therapeutics by 150.8% in the 4th quarter. Renaissance Technologies LLC now owns 32,100 shares of the biotechnology company’s stock worth $174,000 after buying an additional 19,300 shares during the period. 47.43% of the stock is currently owned by institutional investors and hedge funds.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.